Dr. reddy's laboratories announces the launch of capecitabine tablets, usp in the u.s. market

Hyderabad, india and princeton, n.j.--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy along with its subsidiaries together referred to as “dr. reddy's”) today announced the launch of capecitabine tablets, usp a therapeutic equivalent generic version of xeloda (capecitabine) tablets approved by the u.s. food and drug administration (usfda). the xeloda brand and generic had u.s. sales of approximately $90 million mat for the most recent twelv
RDY Ratings Summary
RDY Quant Ranking